Myasthenia gravis (MG) is an acquired disorder of neuromuscular transmission, which occurs due to the production of pathogenic autoantibodies that bind to components of the neuromuscular junction, disrupting nerve signaling and leading to muscle weakness and fatigue. Acetylcholinesterase inhibitors (e.g., pyridostigmine) and short- and long-term immunosuppressants (e.g., prednisone, mycophenolate mofetil, and azathioprine) are the most commonly prescribed agents to manage MG symptoms. However, the MG pipeline is starting to bring novel therapies with unique MOAs to the market, highlighted by the 2017 FDA approval of eculizumab (Soliris). Because we expect multiple therapies to enter the U.S. MG market in the near future, this report offers insights on the projected launch of emerging therapies, company involvement, market predictions, and unmet need to help new players better understand the market niche for their emerging products.
- What is the current treatment algorithm for MG, and how will it change in the next 10 years? How will the launches of late-phase emerging therapies (efgartigimod, amifampridine, rozanolixizumab, zilucoplan) plus the expanded approvals of Ultomiris and Uplizna for MG, impact MG treatment and market access?
- What companies are influencers in the MG market currently and in the future? What market influence do current and emerging therapies have?
- What are the physicians’ insights on current unmet needs in the MG market?
- What are the drivers and limiters of the future MG market?
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Release date: July 2021
Geography: United States
Primary Research: 3 KOL interviews in May 2021
Key companies covered: Alexion, Genentech / Roche, Argenx, Catalyst, UCB, Horizon, Takeda, Immunovant and, Janssen
Key drugs covered: Soliris, rituximab, efgartigimod, amifampridine, rozanolixizumab, zilucoplan, Ultomiris (ravulizumab), Uplizna (inebilizumab), mezagitamab, IMVT-1401, and nipocalimab
- Myasthenia Gravis - Executive Insights - Myasthenia Gravis Executive Insights
- Executive Insights - 2021 - Myasthenia Gravis
Author(s): Preeti Attri
Preeti Attri, Ph.D., is an associate analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. Previously, she was a business analyst in the biopharmaceutical industry. She has experience in market assessment, competitive intelligence, primary market research, pharma forecasting, analogue and indication assessment, disease portfolio optimization, and database research. She obtained her doctorate degree in cancer epigenetics from the National Institute of Immunology in New Delhi.